Bayer Advances Radiology Portfolio with AI and Imaging Innovations at RSNA 2024

Bayer is expecting to showcase new leading advancements in its radiology solutions during the 2024 RSNA Annual Meeting scheduled to take place in Chicago from December 1-5. Of the announcements is the updated Phase III data on gadoquatrane, which is a low-dose macrocyclic gadolinium-based contrast agent under investigational status, targeted at improving diagnostic accuracy in MRI processes. This new agent aims at minimising patients’ exposure to gadolinium but at the same time creating high-quality contrast-enhanced MRIs, a factor of patient safety.

To strengthen cooperation in the sphere of AI use in medical imaging, Bayer has deepened partnership with Subtle Medical. Collectively, they are creating SubtleGAD™, a deep-learning algorithm that aims to minimize the dose of gadolinium-based contrast agents while maintaining image quality. Another product that Bayer will launch is the MEDRAD™ Centargo CT Injection System that recently received the FDA nod on CT imaging operations. CortenicTM Connectivity Platform, one of the new Bayer digital solutions, will be showcased at RSNA, as it aims at managing the workflow integration within radiology departments to increase efficiency of the processes and address the needs of patients.

Here again, Bayer heads towards AI innovations not restricted to imaging only. The new AI Innovation Platform (AIIP) is expected to address the needs of healthcare organisations and start-ups aiming to advance their AI-based software products. Furthermore, Bayer has established new collaborations with data suppliers and has also broadened its offering, the Calantic™ Digital Solutions, which is a suite of AI applications that helps radiologists throughout their daily practice. These efforts show Bayer’s strong commitment to the advancement of radiology, allowing clinicians to deliver the best innovations to further the benefits of patients and address new concerns in the industry.